Yaël C. Cohen

Tel Aviv University — Israel

Medicine · Health Sciences

31h-index4.6kcitations328works4.62yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Multiple Myeloma Research and Treatments(164), Protein Degradation and Inhibitors(62), CAR-T cell therapy research(52), Peptidase Inhibition and Analysis(36), Amyloidosis: Diagnosis, Treatment, Outcomes(29)

Publications327 total

Talquetamab Induces Deep Responses in Heavily Pre-Treated Patients with Systemic Light-Chain Amyloidosis
2026Open Access
Surveillance of Smoldering Myeloma Patients Who Progress to Active Disease Is Associated with Favorable Outcomes
Cancers·2026Open Access
Trial in Progress: QUINTESSENTIAL-2—a phase 3 Study of Arlocabtagene Autoleucel Versus Standard of Care in Adult Patients with Relapsed and Refractory Multiple Myeloma (RRMM) Exposed to Lenalidomide
Transplantation and Cellular Therapy·2026
Attenuated antibody responses to respiratory syncytial virus vaccination in hematologic malignancies: impact of anti-CD20 therapy
Haematologica·2026Open Access
Cilta-cel in lenalidomide-refractory multiple myeloma (CARTITUDE-4): an updated analysis including overall survival from an open-label, multicentre, randomised, phase 3 trial
The Lancet Oncology·2026· 1 citedOpen Access
Extramedullary Disease—Achilles Heel in Myeloma?
American Journal of Hematology·2025Open Access
Dual Targeting of Extramedullary Myeloma with Talquetamab and Teclistamab
New England Journal of Medicine·2025· 3 cited
Outcomes in patients with relapsed/refractory multiple myeloma with extramedullary disease: a meta-analysis
Annals of Hematology·2025Open Access
Supplementary Table 1 from Feasibility of a Novel Academic BCMA-CART (HBI0101) for the Treatment of Relapsed and Refractory AL Amyloidosis
2025Open Access
Supplementary Figures S1-S7 from Feasibility of a Novel Academic BCMA-CART (HBI0101) for the Treatment of Relapsed and Refractory AL Amyloidosis
2025Open Access
Supplementary Data 1 from Feasibility of a Novel Academic BCMA-CART (HBI0101) for the Treatment of Relapsed and Refractory AL Amyloidosis
2025Open Access
Efficacy and safety of talquetamab + teclistamab in patients with Relapsed/Refractory multiple myeloma and extramedullary disease: Updated Phase 2 results from the redirectt-1 study with extended follow-up
Blood·2025Open Access
Talquetamab induces deep responses in heavily pre-treated patients with systemic light-chain amyloidosis
Blood·2025Open Access
Trial in progress: QUINTESSENTIAL-2—a phase 3 study of arlocabtagene autoleucel versus standard of care in adult patients with relapsed and refractory multiple myeloma (RRMM) exposed to lenalidomide
Blood·2025
Safety and efficacy of talquetamab + teclistamab in patients with Relapsed/Refractory multiple myeloma from Phase 1b of redirectt-1: Results with an extended median follow-up of 3 years
Blood·2025Open Access
Updated analysis of survival and treatment evolution in european multiple myeloma patients (2012–2023) across 7 countries from the honeur network
Blood·2025Open Access
Summary analysis of the phase 1a/b study with HBI0101, an academic anti-BCMA chimeric antigen receptor T-cell (CART) for relapsed/refractory multiple myeloma
Blood·2025Open Access
Surzetoclax (ABBV-453) in combination with daratumumab and dexamethasone in biomarker-selected patients with Relapsed/Refractory multiple myeloma: A Phase 1/2, multicenter, open-label platform study
Blood·2025
Daratumumab monotherapy versus active monitoring in patients with high-risk smoldering multiple myeloma: Aquila outcomes based on mayo 2018/IMWG 2020 risk stratification, IMWG 2020 plus cytogenetic criteria, and age
Blood·2025
A plain language summary of the CEPHEUS study of daratumumab plus bortezomib, lenalidomide, and dexamethasone for people with newly diagnosed multiple myeloma who are not expected to receive a stem cell transplant
Future Oncology·2025Open Access
page 1 of 17Next →

Frequent Co-authors

Irit Avivi(22), Moshe E. Gatt(11), Hila Magen(8), Jordan M. Schecter(7), María‐Victoria Mateos(6), Niels W.C.J. van de Donk(6), Hermann Einsele(6), Noa Lavi(6), Adam D. Cohen(6), Kevin C. De Braganca(6), Helen Varsos(6), Muhammad Akram(6), Albert Oriol(5), Efrat Luttwak(5), Tamar Tadmor(5), Christina Corsale(5), Hartmut Goldschmidt(5), Jesús F. San Miguel(4), Sébastien Anguille(4), Wilfried Roeloffzen(4)